Investigating the relationship between BMI across adulthood and late life brain pathologies.
Alzheimer’s disease
Cohort studies
Epidemiology
MRI
PET
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
30 04 2021
30 04 2021
Historique:
received:
02
12
2020
accepted:
12
04
2021
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
25
6
2021
Statut:
epublish
Résumé
In view of reported associations between high adiposity, particularly in midlife and late-life dementia risk, we aimed to determine associations between body mass index (BMI), and BMI changes across adulthood and brain structure and pathology at age 69-71 years. Four hundred sixty-five dementia-free participants from Insight 46, a sub-study of the British 1946 birth cohort, who had cross-sectional T1/FLAIR volumetric MRI, and florbetapir amyloid-PET imaging at age 69-71 years, were included in analyses. We quantified white matter hyperintensity volume (WMHV) using T1 and FLAIR 3D-MRI; β-amyloid (Aβ) positivity/negativity using a SUVR approach; and whole brain (WBV) and hippocampal volumes (HV) using 3D T1-MRI. We investigated the influence of BMI, and BMI changes at and between 36, 43, 53, 60-64, 69 and 71 years, on late-life WMHV, Aβ-status, WBV and mean HV. Analyses were repeated using overweight and obese status. At no time-point was BMI, change in BMI or overweight/obese status associated with WMHV or WBV at age 69-71 years. Decreasing BMI in the 1-2 years before imaging was associated with an increased odds of being β-amyloid positive (OR 1.45, 95% confidence interval 1.09, 1.92). There were associations between being overweight and larger mean HV at ages 60-64 (β = 0.073 ml, 95% CI 0.009, 0.137), 69 (β = 0.076 ml, 95% CI 0.012, 0.140) and 71 years (β = 0.101 ml, 95% CI 0.037, 0.165). A similar, albeit weaker, trend was seen with obese status. Using WMHV, β-amyloid status and brain volumes as indicators of brain health, we do not find evidence to explain reported associations between midlife obesity and late-life dementia risk. Declining BMI in later life may reflect preclinical Alzheimer's disease.
Sections du résumé
BACKGROUND
In view of reported associations between high adiposity, particularly in midlife and late-life dementia risk, we aimed to determine associations between body mass index (BMI), and BMI changes across adulthood and brain structure and pathology at age 69-71 years.
METHODS
Four hundred sixty-five dementia-free participants from Insight 46, a sub-study of the British 1946 birth cohort, who had cross-sectional T1/FLAIR volumetric MRI, and florbetapir amyloid-PET imaging at age 69-71 years, were included in analyses. We quantified white matter hyperintensity volume (WMHV) using T1 and FLAIR 3D-MRI; β-amyloid (Aβ) positivity/negativity using a SUVR approach; and whole brain (WBV) and hippocampal volumes (HV) using 3D T1-MRI. We investigated the influence of BMI, and BMI changes at and between 36, 43, 53, 60-64, 69 and 71 years, on late-life WMHV, Aβ-status, WBV and mean HV. Analyses were repeated using overweight and obese status.
RESULTS
At no time-point was BMI, change in BMI or overweight/obese status associated with WMHV or WBV at age 69-71 years. Decreasing BMI in the 1-2 years before imaging was associated with an increased odds of being β-amyloid positive (OR 1.45, 95% confidence interval 1.09, 1.92). There were associations between being overweight and larger mean HV at ages 60-64 (β = 0.073 ml, 95% CI 0.009, 0.137), 69 (β = 0.076 ml, 95% CI 0.012, 0.140) and 71 years (β = 0.101 ml, 95% CI 0.037, 0.165). A similar, albeit weaker, trend was seen with obese status.
CONCLUSIONS
Using WMHV, β-amyloid status and brain volumes as indicators of brain health, we do not find evidence to explain reported associations between midlife obesity and late-life dementia risk. Declining BMI in later life may reflect preclinical Alzheimer's disease.
Identifiants
pubmed: 33941254
doi: 10.1186/s13195-021-00830-7
pii: 10.1186/s13195-021-00830-7
pmc: PMC8091727
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Subventions
Organisme : Medical Research Council
ID : MC_UU_00019/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00019/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/2
Pays : United Kingdom
Organisme : Medical Research Foundation
ID : CSUB199166
Organisme : Alzheimer's Research UK
ID : ARUK-PG2017-1946
Organisme : Alzheimer's Research UK
ID : ARUK-PG2014-1946
Organisme : Medical Research Council
ID : MC_UU_00019/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/3
Pays : United Kingdom
Organisme : Medical Research Foundation
ID : MC_UU_12019/1, MC_UU_12019/2, MC_UU_12019/3
Références
Neurobiol Aging. 2015 Jan;36 Suppl 1:S194-S202
pubmed: 25248607
BMC Neurol. 2017 Apr 18;17(1):75
pubmed: 28420323
Transl Res. 2017 May;183:57-70
pubmed: 28130064
Neurology. 2017 Nov 14;89(20):2031-2038
pubmed: 29046362
Lancet. 2014 Mar 15;383(9921):970-83
pubmed: 24269108
Am J Epidemiol. 2008 Nov 15;168(10):1179-89
pubmed: 18835864
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Med Image Anal. 2013 Aug;17(6):671-84
pubmed: 23510558
Neurology. 2009 Nov 10;73(19):1559-66
pubmed: 19901247
Nature. 2007 Nov 1;450(7166):106-9
pubmed: 17934448
BMC Res Notes. 2018 Dec 13;11(1):885
pubmed: 30545411
Neurology. 2013 May 28;80(22):2055-61
pubmed: 23635961
Arch Neurol. 2005 Oct;62(10):1556-60
pubmed: 16216938
Am J Epidemiol. 2015 May 1;181(9):672-9
pubmed: 25810457
Neurology. 2005 Sep 27;65(6):892-7
pubmed: 16186530
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Lancet Diabetes Endocrinol. 2015 Jun;3(6):431-436
pubmed: 25866264
Age Ageing. 2016 Jan;45(1):14-21
pubmed: 26764391
Am J Geriatr Psychiatry. 2016 Nov;24(11):1095-1104
pubmed: 27426238
Cell Mol Neurobiol. 2016 Mar;36(2):203-17
pubmed: 26993509
Neuroimage. 2015 Jan 1;104:366-72
pubmed: 25255942
J Alzheimers Dis. 2011;24 Suppl 2:17-25
pubmed: 21335656
Int J Epidemiol. 2016 Aug;45(4):1091-1102
pubmed: 27413103
IEEE Trans Med Imaging. 2015 Oct;34(10):2079-102
pubmed: 25850086
Alzheimers Dement (Amst). 2017 Jun 20;8:165-178
pubmed: 28761927
Alzheimers Dement. 2012 Nov;8(6):470-82
pubmed: 22858531
Int J Epidemiol. 2011 Feb;40(1):e1-9
pubmed: 21345808
Ann Neurol. 2010 Aug;68(2):136-44
pubmed: 20695006
JAMA. 2017 Apr 11;317(14):1443-1450
pubmed: 28399252
Obes Rev. 2018 Feb;19(2):269-280
pubmed: 29024348
Dement Geriatr Cogn Disord. 2011;31(2):119-25
pubmed: 21273771
Neurology. 2007 Aug 21;69(8):739-46
pubmed: 17709705
Alzheimers Dement. 2018 May;14(5):601-609
pubmed: 29169013
J Alzheimers Dis. 2012;28(1):163-71
pubmed: 21965312
Curr Alzheimer Res. 2007 Apr;4(2):103-9
pubmed: 17430231
Ageing Res Rev. 2009 Jan;8(1):18-30
pubmed: 18692159
Neurology. 2011 Nov 22;77(21):1913-20
pubmed: 22105948
J Alzheimers Dis. 2016 Jun 18;53(3):1097-105
pubmed: 27340843
Eur Heart J. 2014 Dec 7;35(46):3287-95
pubmed: 25246483
Arch Neurol. 2009 Mar;66(3):336-42
pubmed: 19273752
Neurology. 2003 Jan 14;60(1):117-9
pubmed: 12525731
Psychol Med. 1979 Feb;9(1):139-45
pubmed: 424481
JAMA Neurol. 2017 Jun 1;74(6):718-726
pubmed: 28418521
Arch Neurol. 2007 Mar;64(3):392-8
pubmed: 17353383
Stroke. 2015 Nov;46(11):3131-6
pubmed: 26451022
Neuroimage. 2011 Apr 1;55(3):1091-108
pubmed: 21195780
Arch Neurol. 2005 Jan;62(1):55-60
pubmed: 15642850
Neurology. 2011 Aug 2;77(5):461-8
pubmed: 21810696